Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial growth factor A (VEGF-A) production that induces a specific vascular phenotype. We previously reported that this phenotype may allow shedding of multicellular tumor fragments into the circ...
Main Authors: | Gursah Kats-Ugurlu, Egbert Oosterwijk, Stijn Muselaers, Jeannette Oosterwijk-Wakka, Christina Hulsbergen-van de Kaa, Mirjam de Weijert, Han van Krieken, Ingrid Desar, Carla van Herpen, Cathy Maass, Rob de Waal, Peter Mulders, William Leenders |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-03-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558614000189 |
Similar Items
-
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
by: Egbert Oosterwijk, et al.
Published: (2013-05-01) -
Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
by: Jeannette C. Oosterwijk-Wakka, et al.
Published: (2015-02-01) -
Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
by: Kazuhiro Nagao, et al.
Published: (2018-11-01) -
Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model
by: J. Falke, et al.
Published: (2018-01-01) -
Optimizing Lutetium 177–Anti–Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model
by: Constantijn H.J. Muselaers, et al.
Published: (2014-06-01)